Get started
Author

Veronica Patton

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2007 · Patrizia Carpinelli, Roberta Ceruti, et al. · Molecular Cancer Therapeutics · 248
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
2008 · Alessia Montagnoli, Barbara Valsasina, et al. · Nature Chemical Biology · 209
Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease.
2009 · E Radaelli, R Ceruti, et al. · PubMed · 106
PDF
Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms
2014 · Alessandra Decio, Giulia Taraboletti, et al. · American Journal Of Pathology · 70
PDF
Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
2010 · Clara Albanese, Rachele Alzani, et al. · Molecular Cancer Therapeutics · 66
Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.
2010 · Ulisse Cucchi, Laura M Gianellini, et al. · PubMed · 60
Efficacy of PHA-848125, a Cyclin-Dependent Kinase Inhibitor, on the K-RasG12DLA2 Lung Adenocarcinoma Transgenic Mouse Model: Evaluation by Multimodality Imaging
2010 · Anna Degrassi, Micaela Russo, et al. · Molecular Cancer Therapeutics · 37
The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia
2013 · Alessia Casolaro, Josee Golay, et al. · PLoS ONE · 35
PDF
Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models
2010 · Rachele Alzani, Olga Pedrini, et al. · Experimental Hematology · 16
Reduced mammary tumor progression in a transgenic mouse model fed an isoflavone‐poor soy protein concentrate
2008 · Giulia Chiesa, Elena Rigamonti, et al. · Molecular Nutrition & Food Research · 12
Diagnostic Exercise: Sudden Death in a Mouse with Experimentally Induced Acute Myeloid Leukemia
2009 · E. Radaelli, F. Marchesi, et al. · Veterinary Pathology · 5
Abstract DD01-01: NMS-1116354: More than an inhibitor of Cdc 7 kinase in S-phase
2010 · Francesco Colotta, Jurgen Moll, et al. · Cancer Research · 1
368 POSTER Discovery and characterization of a new potent orally available Cdc7 inhibitor with anti-tumor activity
2008 · A. Montagnoli, E. Vanotti, et al. · European Journal of Cancer Supplements · 1
Supplementary Data from Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
2023 · Clara Albanese, Rachele Alzani, et al.
PDF
Data from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023 · Patrizia Carpinelli, Roberta Ceruti, et al.
Data from Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
2023 · Clara Albanese, Rachele Alzani, et al.
Data from Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
2023 · Clara Albanese, Rachele Alzani, et al.
Data from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023 · Patrizia Carpinelli, Roberta Ceruti, et al.
Supplementary Table S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023 · Patrizia Carpinelli, Roberta Ceruti, et al.
PDF
Supplementary Fig. S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023 · Patrizia Carpinelli, Roberta Ceruti, et al.
PDF
Supplementary Data from Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
2023 · Clara Albanese, Rachele Alzani, et al.
Abstract A179: NMS-P113, a novel orally available JAK2 selective inhibitor
2015 · Paola Gnocchi, Maria Gabriella Brasca, et al. · Molecular Cancer Therapeutics
Works count: 22
Citation count: 866
H-index: 10
I10-index: 10
Year
Topic
Type